BIOTECH

BIOTECH

Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®

Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up...

Read more

BIOTECH

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision...

Read more

BIOTECH

AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V

The transaction reflects a pre-money equity value of $400 million for AUM Biosciences Transaction is...

Read more

BIOTECH

Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01

Precision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders...

Read more

BIOTECH

AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene

SINGAPORE and BETHESDA, Md., Aug. 18, 2022 (GLOBE NEWSWIRE) — AUM Biosciences, a global clinical-stage...

Read more